Next Article in Journal
Fewer Cardiopulmonary Complications and Shorter Length of Stay in Anterolateral Thoracolumbar Spine Exposures Using a Small-Incision Specialized Retractor System
Next Article in Special Issue
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
Previous Article in Journal
Menstrual Phase Affects Coagulation and Hematological Parameters during Central Hypovolemia
Previous Article in Special Issue
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 10
10.3390/jcm9103120
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

by
María-Victoria Mateos
1,
Joan Bladé
2,
Sara Bringhen
3,
Enrique M Ocio
4,
Yvonne Efebera
5,
Luděk Pour
6,
Francesca Gay
3,
Pieter Sonneveld
7,
Joachim Gullbo
8 and
Paul G. Richardson
9,*
1
Hospital Clínico Universitario de Salamanca/IBSAL/CIC, 37007 Salamanca, Spain
2
Hematology Department, Institut d’Investigacions Biomèdiques August Pi I Sunyer, Hospital Clinic, 08036 Barcelona, Spain
3
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy
4
University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, 39008 Santander, Spain
5
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
6
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 62500 Brno, Czech Republic
7
Erasmus MC Cancer Institute, 3075 EA Rotterdam, The Netherlands
8
Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, 751 85 Uppsala, Sweden
9
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(10), 3120; https://doi.org/10.3390/jcm9103120
Submission received: 27 July 2020 / Revised: 15 September 2020 / Accepted: 23 September 2020 / Published: 27 September 2020
(This article belongs to the Special Issue New Therapies and Therapeutic Approaches in Multiple Myeloma)
Browse Figure
Versions Notes

Abstract

Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options after second-line treatment. Melflufen (melphalan flufenamide) is a first-in-class peptide–drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Once inside the tumor cells, melflufen is hydrolyzed by peptidases to release alkylator molecules, which become entrapped. Melflufen showed anti-myeloma activity in myeloma cells that were resistant to bortezomib and the alkylator melphalan. In early phase studies (O-12-M1 and HORIZON [OP-106]), melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma, including those with triple-class refractory disease and extramedullary disease. The Phase III OCEAN study (OP-104) is further evaluating melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma. The safety profile of melflufen is characterized primarily by clinically manageable hematologic adverse events. Melflufen, with its novel mechanism of action, has the potential to provide clinically meaningful benefits to patients with relapsed/refractory multiple myeloma, including those with high unmet needs.
Keywords: melflufen; melphalan flufenamide; peptide–drug conjugate; multiple myeloma; new drugs; drug combinations melflufen; melphalan flufenamide; peptide–drug conjugate; multiple myeloma; new drugs; drug combinations

Share and Cite

MDPI and ACS Style

Mateos, M.-V.; Bladé, J.; Bringhen, S.; Ocio, E.M.; Efebera, Y.; Pour, L.; Gay, F.; Sonneveld, P.; Gullbo, J.; Richardson, P.G. Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma. J. Clin. Med. 2020, 9, 3120. https://doi.org/10.3390/jcm9103120

AMA Style

Mateos M-V, Bladé J, Bringhen S, Ocio EM, Efebera Y, Pour L, Gay F, Sonneveld P, Gullbo J, Richardson PG. Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine. 2020; 9(10):3120. https://doi.org/10.3390/jcm9103120

Chicago/Turabian Style

Mateos, María-Victoria, Joan Bladé, Sara Bringhen, Enrique M Ocio, Yvonne Efebera, Luděk Pour, Francesca Gay, Pieter Sonneveld, Joachim Gullbo, and Paul G. Richardson. 2020. "Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma" Journal of Clinical Medicine 9, no. 10: 3120. https://doi.org/10.3390/jcm9103120

APA Style

Mateos, M.-V., Bladé, J., Bringhen, S., Ocio, E. M., Efebera, Y., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., & Richardson, P. G. (2020). Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine, 9(10), 3120. https://doi.org/10.3390/jcm9103120

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop